Pancreatic Cancer Research

ResearcherInsermActive in the last 2 years

Côme Lepage

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9211-4707; OpenAlex author ID A5032193447. Sources: ClinicalTrials.gov.

Their work

Papers
9
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2015: 1 paper, 1 trial · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 9

  1. Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic… Co-author DOI 10.1016/j.eclinm.2026.103998↗
  2. Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer. Co-author DOI 10.1093/oncolo/oyae079↗
  3. Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma. Co-author DOI 10.21037/jgo-22-946↗
  4. Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1093/oncolo/oyac055↗
  5. Management and Outcomes of Pancreatic Cancer in French Real-World Clinical Practice. Co-author DOI 10.3390/cancers14071675↗
  6. Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial. Co-author DOI 10.1200/jco.20.03329↗
  7. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma… Co-author DOI 10.1016/j.ejca.2020.05.018↗
  8. [Epidemiology of pancreatic cancer]. Co-author DOI 10.1016/j.bulcan.2017.11.004↗
  9. Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999-2007: Results of EUROCAR… Co-author DOI 10.1016/j.ejca.2015.07.034↗

Trials 1

  1. A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET) Principal investigator NCT02288377↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jean‐Baptiste Bachet · 4 shared papers, 2021–2026 · strength 0.61
  2. Sylvain Manfrédi · 3 shared papers, 2018–2023 · strength 0.40
  3. Julien Taı̈eb · 2 shared papers, 2022–2026 · strength 0.38
  4. Yves Rinaldi · 2 shared papers, 2021–2026 · strength 0.33
  5. François Ghiringhelli · 2 shared papers, 2022–2023 · strength 0.28
  6. Anne‐Marie Bouvier · 2 shared papers, 2018–2022 · strength 0.27
  7. Laëtitia Dahan · 2 shared papers, 2021–2022 · strength 0.26
  8. Antoine Drouillard · 2 shared papers, 2018–2023 · strength 0.24
  9. Carole Vitellius · 1 shared paper, 2026 · strength 0.22
  10. Frédéric Di Fiore · 1 shared paper, 2026 · strength 0.22
  11. Anna Pellat · 1 shared paper, 2026 · strength 0.22
  12. Simon Pernot · 1 shared paper, 2026 · strength 0.22
  13. David Tougeron · 1 shared paper, 2026 · strength 0.22
  14. Clémence Canton · 1 shared paper, 2022 · strength 0.16
  15. Olivier Facy · 1 shared paper, 2022 · strength 0.16
  16. Valérie Jooste · 1 shared paper, 2022 · strength 0.16
  17. Noelle K. LoConte · 1 shared paper, 2023 · strength 0.12
  18. Jerome F. Cros · 1 shared paper, 2023 · strength 0.12
  19. David Piquemal · 1 shared paper, 2023 · strength 0.12
  20. Christophe Tournigand · 1 shared paper, 2023 · strength 0.12
  21. Emmanuelle Kempf · 1 shared paper, 2023 · strength 0.12
  22. Émilie Soularue · 1 shared paper, 2023 · strength 0.12
  23. Cindy Canivet · 1 shared paper, 2023 · strength 0.12
  24. Isabelle Trouilloud · 1 shared paper, 2023 · strength 0.12
  25. Barbara Bournet · 1 shared paper, 2023 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.